Mga Batayang Estadistika
| CIK | 1768224 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Arcturus Therapeutics Holdings Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 29, 2025 |
August 29, 2025 Meiji Seika Pharma Receives Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine Meiji Seika Pharma Co. |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| August 11, 2025 |
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress Cystic fibrosis (ARCT-032) Phase 2 interim data from first nine participants to be presented in September Cystic fibrosis Phase 2 trial expected to complete enrollment by year end 2025 OTC deficiency (ARCT-810) Phase 3 trial design alignment with regulatory agencies expected H1 2026 Seasonal flu (ARCT-2138) showed positive Phase 1 results BARDA pandemic flu (ARCT-2304) Phase 1 results expected 2025 Investor conference call at 4:30 p. |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q cs UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| June 30, 2025 |
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program ARCT-810 significantly and consistently reduces biomarker glutamine to levels within normal range 15N-ureagenesis data provide first evidence of an mRNA therapeutic improving urea cycle function Ammonia remained stable and within normal range Multiple administrations of ARCT-810 continue to be safe and well tolerated at all tested dose levels Virtual KOL Presentation at 12:00 p. |
|
| June 30, 2025 | ||
| June 30, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) (C |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q cs UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| May 12, 2025 |
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress Prioritization of mRNA therapeutics pipeline extends cash runway into 2028 ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025 ARCT-032 (CF) Phase 2 expected to complete enrollment by year end ARCT-810 (OTC) Phase 2 interim data expected Q2 2025 Investor conference call at 4:30 p. |
|
| May 12, 2025 |
FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (this “Fifth Amendment”) is made as of July , 2024, by 12 and between ARE-SD REGION NO. |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) (C |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden |
|
| March 6, 2025 |
Description of Registrant’s Securities. Exhibit 4.1 ARCTURUS THERAPEUTICS HOLDINGS INC. DESCRIPTION OF SECURITIES Arcturus Therapeutics Holdings Inc. (“we,” “our,” “us,” or the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following description summarizes important terms of our common stock. For a complete description, you should refer to our |
|
| March 6, 2025 |
List of subsidiaries of Arcturus Therapeutics Holdings, Inc. Exhibit 21.1 Subsidiaries of the Registrant Set forth below is a list of subsidiaries of Arcturus Therapeutics Holdings Inc. (the “Registrant”) All of the subsidiaries listed below are wholly-owned subsidiaries of the Registrant and are owned directly by the Registrant. Subsidiary Jurisdiction of Formation Arcturus Therapeutics, Inc. Delaware Arcturus Therapeutics Asia Pte. Ltd. Singapore Arcturus |
|
| March 6, 2025 |
Arcturus Therapeutics Holdings, Inc. Clawback Policy Exhibit 97.1 ARCTURUS THERAPEUTICS HOLDINGS INC. CLAWBACK POLICY 1. Introduction Arcturus Therapeutics Holdings Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to create and foster a culture of business ethics, integrity and accountability, and that, among other purposes, reinforces the Company’s incentive compensation philosophy. The Board of Dir |
|
| March 6, 2025 |
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress Phase 2 interim data for ARCT-032 (CF) & ARCT-810 (OTCD) on track for Q2 2025 Meiji Seika Pharma and ARCALIS received MHLW approval for commercial manufacturing of KOSTAIVE® Meiji Seika Pharma Submitted Application for Two-Dose Vial of KOSTAIVE® KOSTAIVE® U. |
|
| March 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K reportp UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission File Number 001-38942 ARCTURU |
|
| March 6, 2025 |
Arcturus Therapeutics Holdings, Inc. Insider Trading Policy Exhibit 19.1 Effective January 1, 2024 ARCTURUS THERAPEUTICS HOLDINGS INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Company Information and Certain Transactions in Company Securities Purpose This Insider Trading Policy (this “Policy”) provides guidelines with respect to transactions in the securities of Arcturus Therapeutics Holdings Inc. (including subsidiaries where applicab |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* Arcturus Therapeutics Holdings Inc (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03969T109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| November 7, 2024 |
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress Cystic Fibrosis and OTC Deficiency Phase 2 studies on track for POC data in first half of 2025 $25 Million commercial milestone achieved with first sale of KOSTAIVE® in Japan KOSTAIVE® European CHMP opinion expected December Positive results from multiple Phase 3 studies support KOSTAIVE® U. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q cs UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation |
|
| November 7, 2024 |
FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (this “Fifth Amendment”) is made as of July , 2024, by 12 and between ARE-SD REGION NO. |
|
| November 5, 2024 |
ARCT / Arcturus Therapeutics Holdings Inc. / Sumitomo Mitsui Trust Holdings, Inc. Passive Investment SC 13G 1 arct1027246sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* Arcturus Therapeutics Holdings Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 03969T109 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statemen |
|
| August 13, 2024 | ||
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q cs UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| August 5, 2024 |
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress IND submitted for Phase 2 trial of ARCT-032 targeting cystic fibrosis (CF) ARCT-810 (OTC deficiency) Phase 2 interim data on track for Q4 Kostaive® on track for Q4 commercial launch in Japan Investor conference call at 4:30 p. |
|
| August 5, 2024 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Exhibit 10. |
|
| August 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| July 17, 2024 |
As filed with the Securities and Exchange Commission on July 17, 2024 As filed with the Securities and Exchange Commission on July 17, 2024 Registration No. |
|
| July 17, 2024 |
Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended ARCTURUS THERAPEUTICS HOLDINGS INC. AMENDED & RESTATED 2019 OMNIBUS EQUITY INCENTIVE PLAN (Originally Effective June 10, 2019; Amended & Restated Effective June 5, 2020; Amended Effective June 21, 2022; Amended Effective June 14, 2024) ARTICLE 1. EFFECTIVE DATE, OBJECTIVES AND DURATION 1.1 Effective Date of the Plan. The Board of Directors of ARCTURUS THERAPEUTICS HOLDINGS INC., a Delaware corpora |
|
| July 17, 2024 |
CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Arcturus Therapeutics Holdings Inc. |
|
| June 24, 2024 |
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors Previously Chief Scientific Advisor for Operation Warp Speed, advised U.S. President's Council of Advisors on Science and Technology, member of Advisory Committee to the Director of the NIH SAN DIEGO-(BUSINESS WIRE)-June 20, 2024- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messen |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2024 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| June 14, 2024 |
ARCTURUS THERAPEUTICS HOLDINGS INC. AMENDED & RESTATED 2019 OMNIBUS EQUITY INCENTIVE PLAN (Originally Effective June 10, 2019; Amended & Restated Effective June 5, 2020; Amended Effective June 21, 2022; Amended Effective June 14, 2024) ARTICLE 1. EFFECTIVE DATE, OBJECTIVES AND DURATION 1.1 Effective Date of the Plan. The Board of Directors of ARCTURUS THERAPEUTICS HOLDINGS INC., a Delaware corpora |
|
| May 8, 2024 |
REDACTED Certain identified information, indicated by [***], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q cs UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) (Co |
|
| May 8, 2024 |
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress Commercial manufacture of Kostaive® on track for delivery of initial 4 million doses in Q3 Kostaive® European Marketing Authorization Application approval decision expected Q3 Multiple Kostaive® Phase 3 trials further demonstrate breadth and durability of STARR® vaccine platform ARCT-2138 (LUNAR-FLU) Phase 1 topline immunogenicity and safety data, anticipated in Q3 ARCT-810 (LUNAR-OTC) Phase 2 and ARCT-032 (LUNAR-CF) Phase 1b interim data and update to be provided on July 1st JP Morgan engaged to monetize investment in ARCALIS JV in Japan Investor conference call at 4:30 p. |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confiden |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| April 5, 2024 |
Letter from Ernst & Young LLP to the Securities and Exchange Commission dated April 5, 2024 April 5, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated April 5, 2024, of Arcturus Therapeutics Holdings, Inc. and are in agreement with the statements contained in the second and third paragraphs on page 1 therein. We have no basis to agree or disagree with other statements of the registrant contained therein |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| March 19, 2024 |
March 19, 2024 Positive Results of Phase III Study of Bivalent Version of Kostaive®, Self-Amplifying mRNA Vaccine Against COVID-19 (Ancestral Strain and Omicron BA. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission File Number 001-38942 ARCTURUS THERAP |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction o |
|
| March 14, 2024 |
Arcturus Therapeutics Holdings, Inc. Clawback Policy Exhibit 97.1 ARCTURUS THERAPEUTICS HOLDINGS INC. CLAWBACK POLICY 1. Introduction Arcturus Therapeutics Holdings Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to create and foster a culture of business ethics, integrity and accountability, and that, among other purposes, reinforces the Company’s incentive compensation philosophy. The Board of Dir |
|
| March 14, 2024 |
Description of Registrant’s Securities. Exhibit 4.1 Common Stock As of March 21, 2023, there were 26,555,843 shares of common stock outstanding. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. The holders of common stock are not entitled to cumulative voting rights with respect to the election of directors, and as a consequence, minority stock |
|
| March 14, 2024 |
Arcturus Therapeutics Holdings, Inc. Insider Trading Policy Exhibit 19.1 Effective January 1, 2024 ARCTURUS THERAPEUTICS HOLDINGS INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Company Information and Certain Transactions in Company Securities Purpose This Insider Trading Policy (this “Policy”) provides guidelines with respect to transactions in the securities of Arcturus Therapeutics Holdings Inc. (including subsidiaries where applicab |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| March 7, 2024 |
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress Kostaive® anticipated to launch in Japan this year ARCT-032 remains on track for Phase 1b interim data in Q2 ARCT-810 remains on track for Phase 2 interim data by the end of Q2 ARCT-2138 (Quadrivalent LUNAR-FLU) Phase 1 study for seasonal influenza vaccine initiated New STARR® vaccine discovery programs initiated for Lyme Disease and Gonorrhea Cash runway extended to Q1 2027 Investor conference call at 4:30 p. |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporatio |
|
| February 13, 2024 |
ARCT / Arcturus Therapeutics Holdings Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Arcturus Therapeutics Holdings Inc Title of Class of Securities: Common Stock CUSIP Number: 03969T109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Sched |
|
| February 12, 2024 |
SC 13G/A 1 ef20021441sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Arcturus Therapeutics Holdings Inc (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03969T109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this S |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Arcturus Therapeutics Holdings Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 03969T109 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 17, 2024 |
ARCT / Arcturus Therapeutics Holdings Inc. / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 arct1567-form.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) ARCTURUS THERAPEUTICS HOLDINGS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03969T109 (CUSIP Number) December 31, 2023 |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q cs UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| November 14, 2023 |
REDACTED Certain identified information, indicated by [***], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. |
|
| November 14, 2023 |
REDACTED Certain identified information, indicated by [***], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. |
|
| November 14, 2023 |
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress Expected cash runway extended to the end of 2026 $35 million milestone achieved under CSL collaboration ARCT-154 remains on track for Japan-NDA approval in December Enrollment target reached in Phase 3 bivalent COVID vaccine comparison trial Enrollment initiated in ARCT-032 Phase 1b study; dosing first cystic fibrosis patient this month ARCT-032 received Rare Pediatric Disease Designation for cystic fibrosis from the FDA Investor conference call at 4:30 p. |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporatio |
|
| October 10, 2023 |
ARCT / Arcturus Therapeutics Holdings Inc / STATE STREET CORP Passive Investment SC 13G/A 1 ArcturusTheraHoldInc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING ARCTURUS THERAPEUTICS HOLDINGS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 03969T109 (CUSIP NUMBER) 09/30/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIG |
|
| September 26, 2023 |
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis CF Foundation Increases Financial Commitment to ~$25 Million SAN DIEGO-(BUSINESS WIRE)-Sept. |
|
| September 26, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporati |
|
| August 14, 2023 |
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government LUNAR-FLU collaboration with CSL Seqirus achieves additional $17. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| August 7, 2023 |
Up to $200,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-269003 Supplement dated August 7, 2023 To Prospectus dated December 30, 2022 Up to $200,000,000 Common Stock This supplement (this “Supplement”) supplements the prospectus, dated December 30, 2022 (the “Prospectus”), relating to the offer and sale of shares of common stock, par value $0.001 per share, of Arcturus Therapeutics Holdings Inc. (the |
|
| August 7, 2023 |
SECURITY AGREEMENT (SECURITIES ACCOUNT) CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EXHIBIT 10. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q cs UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| August 7, 2023 |
ARCTURUS THERAPEUTICS HOLDINGS INC. AMENDMENT NO. 1 TO Controlled Equity OfferingSM Sales Agreement August 7, 2023 CANTOR FITZGERALD & CO. 499 Park Avenue New York, NY 10022 WELLS FARGO SECURITIES, LLC 30 Hudson Yards New York, New York 10001 William Blair & Company, L.L.C. 150 N. Riverside Plaza Chicago, Illinois 60606 Ladies and Gentlemen: Reference is made to the Controlled Equity OfferingSM Sa |
|
| August 7, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EXHIBIT 10. |
|
| August 7, 2023 |
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress ARCT-154 Phase 3 COVID-19 booster trial achieved primary endpoint demonstrating strong immune response and favorable safety profile Meiji Seika Pharma submitted ARCT-154 New Drug Application in Japan New ARCT-154 booster clinical data demonstrate one-year durability across a panel of variants Received FDA Fast Track Designation and Rare Pediatric Disease Designation for ARCT-810 for OTC deficiency Received regulatory approval of ARCT-032 to proceed into a Phase 1b clinical study in CF patients Investor conference call at 4:30 p. |
|
| August 7, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EXHIBIT 10. |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| June 30, 2023 |
June 30, 2023 Name of Company: Meiji Holdings Co., Ltd. Name of Representative: Kazuo Kawamura, CEO, President and Representative Director Code Number: 2269, Prime Market, Tokyo Stock Exchange Additional Application for Booster Dose of ARCT-154, Self-Amplifying mRNA Vaccine against COVID-19, Submitted in Japan Meiji Holdings Co., Ltd. Announces that its subsidiary, Meiji Seika Pharma Co., Ltd., su |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| May 9, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EXHIBIT 10. |
|
| May 9, 2023 |
Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress New Drug Application (NDA) for ARCT-154, a next generation COVID-19 vaccine, was submitted in Japan, leading to potential approval in 2023 $23. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) (Co |
|
| May 9, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EXHIBIT 10. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q cs UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| May 9, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EXHIBIT 10. |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| April 28, 2023 |
April 28, 2023 Name of Company: Meiji Holdings Co., Ltd. Name of Representative: Kazuo Kawamura, CEO, President and Representative Director Code Number: 2269, Prime Market, Tokyo Stock Exchange Submitted New Drug Application to Manufacture and Market ARCT-154, Next Generation mRNA Vaccine against COVID-19, in Japan Meiji Holdings Co., Ltd. announces that its subsidiary, Meiji Seika Pharma Co., Ltd |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2023 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| April 11, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| March 29, 2023 |
Description of Registrant’s Securities. Exhibit 4.1 Common Stock As of March 21, 2023, there were 26,555,843 shares of common stock outstanding. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. The holders of common stock are not entitled to cumulative voting rights with respect to the election of directors, and as a consequence, minority stock |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission File Number 001-38942 ARCTURUS THERAP |
|
| March 29, 2023 |
CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([***]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| March 28, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| March 28, 2023 |
Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress $200 million upfront payment received in December 2022 from CSL collaboration Achieved $90 million in development milestones in March 2023 under CSL collaboration ARCT-154 Phase 3 COVID-19 booster trial enrollment completed in Japan Multiple patients enrolled in ARCT-810 Phase 2 multiple ascending dose trial for OTC deficiency ARCT-032 Phase 1 Cystic Fibrosis trial initiated and enrollment of first two cohorts successfully completed Investor conference call at 4:30 p. |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| February 10, 2023 |
ARCT / Arcturus Therapeutics Ltd. / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 10, 2023 |
SC 13G/A 1 brhc10047811sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Arcturus Therapeutics Holdings Inc (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03969T109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this |
|
| February 9, 2023 |
ARCT / Arcturus Therapeutics Ltd. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Arcturus Therapeutics Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 03969T109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rul |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Arcturus Therapeutics Holdings Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 03969T109 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| February 1, 2023 |
ARCT / Arcturus Therapeutics Ltd. / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 form817.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) ARCTURUS THERAPEUTICS HOLDINGS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03969T109 (CUSIP Number) December 31, 2022 (Date |
|
| December 30, 2022 |
CORRESP 1 filename1.htm December 30, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Arcturus Therapeutics Holdings Inc. Registration Statement on Form S-3 File No. 333-269003 Acceleration Request Requested Date: December 30, 2022 Requested Time: 5:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule |
|
| December 27, 2022 |
December 27, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 23, 2022 |
Calculation of Filing Fee Tables Form S-3 (Form Type) Arcturus Therapeutics Holdings Inc. |
|
| December 23, 2022 |
ARCTURUS THERAPEUTICS HOLDINGS INC. Issuer AND as Trustee INDENTURE Dated as of , 2022 Debt Securities CROSS-REFERENCE TABLE(1) SECTION OF TRUST INDENTURE ACT OF 1939, AS AMENDED SECTION(S) OF INDENTURE 310(a) 7.9 310(b) 7.8 311(a) 7.13 311(b) 7.13 312(a) 5.1, 5.2(a) 312(b) 5.2(b) 312(c) 5.2(c) 313(a) 5.4 313(b) 5.4 313(c) 5.4 313(d) 5.4 314(a) 5.3, 14.12 314(c) 14.7(a) 314(e) 14.7(b) 315(a) 7.1 3 |
|
| December 23, 2022 |
As filed with the U.S. Securities and Exchange Commission on December 23, 2022 As filed with the U.S. Securities and Exchange Commission on December 23, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 32-0595345 (State or Other Jurisdiction of Incorporatio |
|
| December 23, 2022 |
Execution Version ARCTURUS THERAPEUTICS HOLDINGS INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement December 23, 2022 CANTOR FITZGERALD & CO. 499 Park Avenue New York, NY 10022 WELLS FARGO SECURITIES, LLC 500 West 33rd Street, 14th Floor New York, New York 10001 Ladies and Gentlemen: Arcturus Therapeutics Holdings Inc., a Delaware corporation (the |
|
| December 13, 2022 |
Arcturus Appoints John Markels, Ph.D. to its Board of Directors Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company?s vaccine franchise San Diego, Calif., December 13, 2022 ? Arcturus Therapeutics Holdings Inc. (the ?Company?, ?Arcturus?, Nasdaq: ARCT), a global late-stage clinical messenge |
|
| December 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation |
|
| November 9, 2022 |
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress Entered into global partnership with CSL to develop and commercialize self-amplifying mRNA vaccines targeting COVID-19, influenza, additional pathogens, and pandemic preparedness with $200 million upfront and up to $4. |
|
| November 9, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| November 9, 2022 |
2. CONTRACT (Proc. Inst. Ident.) NO. 3. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQUEST/PROJECT NO. 75A50122C00007 See Block 20C OS296560 5. ISSUED BY CODE ASPR-BARDA 6. ADMINISTERED BY (If other than Item 5) CODE ASPR-BARDA 200 Independence Ave., S.W. [***] 17. X CONTRACTOR' S NEGOTIATED AGREEMENT (Contractor is required to sign this document and return copies to issuing office.) Contractor agrees |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation |
|
| November 4, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 33-0595345 (State or other jurisdiction of incorporation |
|
| November 2, 2022 |
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines · Arcturus to receive upfront payment of $200 million and more than $4 billion in potential development and commercial milestones · 40% profit sharing for COVID-19 vaccines, up to double digit royalties for influenza, pandemic preparedness and three additional respiratory infectious disease vaccines · Combines Arcturus’ self-amplifying mRNA vaccine technologies with CSL’s world-leading capabilities as a commercial scale manufacturer and global distributor of influenza and pandemic vaccines San Diego, Calif, November 1, 2022 – Arcturus Therapeutics Holdings Inc. |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 33-0595345 (State or other jurisdiction of incorporation |
|
| September 1, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 33-0595345 (State or other jurisdiction of incorporation) |
|
| September 1, 2022 |
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response ? Arcturus will expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform with the support of the Biomedical Advanced Research and Development Aut |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| August 9, 2022 |
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress New ARCT-154 clinical booster data demonstrate promising durability; 44- and 39-fold increases in neutralizing antibody response against Omicron BA. |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| June 30, 2022 |
CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Arcturus Therapeutics Holdings Inc. |
|
| June 30, 2022 |
ARCTURUS THERAPEUTICS HOLDINGS INC. AMENDED & RESTATED 2019 OMNIBUS EQUITY INCENTIVE PLAN (Originally Effective June 10, 2019; Amended & Restated Effective June 5, 2020; Amended Effective June 21, 2022) ARTICLE 1. EFFECTIVE DATE, OBJECTIVES AND DURATION 1.1 Effective Date of the Plan. The Board of Directors of ARCTURUS THERAPEUTICS HOLDINGS INC., a Delaware corporation (the ?Company?), originally |
|
| June 30, 2022 |
As filed with the Securities and Exchange Commission on June 30, 2022 As filed with the Securities and Exchange Commission on June 30, 2022 Registration No. |
|
| June 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| June 24, 2022 |
ARCTURUS THERAPEUTICS HOLDINGS INC. AMENDED & RESTATED 2019 OMNIBUS EQUITY INCENTIVE PLAN (Originally Effective June 10, 2019; Amended & Restated Effective June 5, 2020; Amended Effective June 21, 2022) ARTICLE 1. EFFECTIVE DATE, OBJECTIVES AND DURATION 1.1 Effective Date of the Plan. The Board of Directors of ARCTURUS THERAPEUTICS HOLDINGS INC., a Delaware corporation (the ?Company?), originally |
|
| May 12, 2022 |
DEFR14A 1 e621618defr14a-arct.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) (Co |
|
| May 9, 2022 |
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress ARCT-154 booster data show 54- and 46-fold increases in neutralizing antibody response against Omicron BA. |
|
| May 9, 2022 |
Exhibit 10.36 SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Sixth Amendment to Loan and Security Agreement (this ?Amendment?) is entered into as of April , 2022, by and between WESTERN ALLIANCE BANK, an Arizona corporation (?Bank?), and ARCTURUS THERAPEUTICS, INC., a Delaware corporation (?Borrower?). RECITALS Borrower and Bank are parties to that certain Loan and Security Agreement dated as |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| May 2, 2022 |
DEF 14A 1 e621607def14a-arct.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permit |
|
| April 20, 2022 |
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study April 20, 2022 at 7:30 AM EDT 95% Efficacy overall for prevention of severe COVID-19 disease including related deaths 55% Efficacy overall for preventing symptomatic COVID-19 disease Study conducted when Delta and Omicron variants were dominant in Vietnam Incidence of unsolicited adverse events with ARCT-154 similar to placebo; No reported cases of myocarditis or pericarditis ARCT-154 to advance into a pivotal booster trial in major markets SAN DIEGO-(BUSINESS WIRE)-Apr. |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2022 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| March 1, 2022 |
Description of Registrant’s Securities. Exhibit 4.1 Common Stock As of February 23, 2022, there were 26,375,002 shares of common stock outstanding. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. The holders of common stock are not entitled to cumulative voting rights with respect to the election of directors, and as a consequence, minority st |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38942 ARCTURUS THERAP |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporatio |
|
| February 28, 2022 |
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress Emergency Use Authorization (EUA) application for ARCT-154 submitted to Vietnam Ministry of Health ARCT-154 Phase 1/2 booster study data in U. |
|
| February 17, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporatio |
|
| February 17, 2022 | ||
| February 15, 2022 |
VLON / Vallon Pharmaceuticals Inc. / Arcturus Therapeutics Holdings Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VALLON PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92023M101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 14, 2022 |
ARCT / Arcturus Therapeutics Ltd. / Nikko Asset Management Americas, Inc. - SC13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* Arcturus Therapeutics Holdings Inc (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 03969T109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 14, 2022 |
ARCT / Arcturus Therapeutics Ltd. / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) ARCTURUS THERAPEUTICS HOLDINGS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03969T109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2022 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation |
|
| February 9, 2022 |
ARCT / Arcturus Therapeutics Ltd. / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 4, 2022 |
ARCT / Arcturus Therapeutics Ltd. / Sumitomo Mitsui Trust Holdings, Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* Arcturus Therapeutics Holdings Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 03969T109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| January 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation |
|
| December 13, 2021 |
Arcturus Therapeutics Holdings Inc. Code of Conduct and Ethics CODE OF BUSINESS CONDUCT AND ETHICS Policy ID# [ ] Last Edited: December 6, 2021 Purpose of Policy Why do we have this Code? Arcturus Therapeutics Holdings Inc. |
|
| December 13, 2021 |
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors SAN DIEGO-(BUSINESS WIRE)-Dec. 13, 2021- Arcturus Therapeutics Holdings Inc. (the ?Company?, ?Arcturus?, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, |
|
| December 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2021 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation |
|
| November 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporatio |
|
| November 16, 2021 | ||
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| November 9, 2021 |
Exhibit 10.34 FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Fifth Amendment to Loan and Security Agreement (this ?Amendment?) is entered into as of October 27, 2021, by and between WESTERN ALLIANCE BANK, an Arizona corporation (?Bank?), and ARCTURUS THERAPEUTICS, INC., a Delaware corporation (?Borrower?). RECITALS Borrower and Bank are parties to that certain Loan and Security Agreement date |
|
| November 9, 2021 |
Exhibit 10.35 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. THE BOARDWALK LEASE This Lease (the ?Lease?), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the ?Summary?), below, is made by and between TPSC IX, LLC, a De |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation |
|
| November 8, 2021 |
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress Phase 1/2/3a and 3b study of ARCT-154 COVID-19 vaccine candidate completed enrollment with over 17,000 participants Initiated ~2,000 participant ARCT-154 Phase 3c sub-study to compare immunogenicity noninferiority to AstraZeneca COVID-19 vaccine; enrollment to be completed this week Preparing to file Emergency Use Authorization (EUA) application for ARCT-154, pending interim study results, with the Vietnam Ministry of Health in December 2021; potential for EUA approval in Q1 2022 Investor conference call at 4:30 p. |
|
| November 1, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2021 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation |
|
| October 26, 2021 |
ARCT / Arcturus Therapeutics Ltd. / Ultragenyx Pharmaceutical Inc. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) ARCTURUS THERAPEUTICS HOLDINGS INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03969T109 (CUSIP Number) Karah Parschauer Executive Vice President, General Counsel Ultragenyx Pharmaceutical Inc. 60 Lev |
|
| October 20, 2021 |
As filed with the Securities and Exchange Commission on October 20, 2021 As filed with the Securities and Exchange Commission on October 20, 2021 Registration No. |
|
| October 20, 2021 |
EXHIBIT 4.1 ARCTURUS THERAPEUTICS HOLDINGS INC. 2021 INDUCEMENT EQUITY INCENTIVE PLAN ARTICLE 1. EFFECTIVE DATE, OBJECTIVES AND DURATION 1.1 Effective Date of the Plan. The Board of Directors of Arcturus Therapeutics Holdings Inc., a Delaware corporation (the ?Company?), has adopted the 2021 Inducement Equity Incentive Plan (the ?Plan?) effective as of October 15, 2021 (the ?Effective Date?). It i |
|
| October 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2021 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporati |
|
| August 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2021 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| August 12, 2021 |
ARCT / Arcturus Therapeutics Ltd. / Ultragenyx Pharmaceutical Inc. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) ARCTURUS THERAPEUTICS HOLDINGS INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03969T109 (CUSIP Number) Karah Parschauer Executive Vice President, General Counsel Ultragenyx Pharmaceutical Inc. 60 Lev |
|
| August 10, 2021 |
EXHIBIT 10.32 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. TECHNOLOGY LICENSE AND TECHNICAL SUPPORT AGREEMENT This TECHNOLOGY LICENSE AND TECHNICAL SUPPORT AGREEMENT (this ?Agreement?), with a signature date of the 29th day of July, 2021 (the ?Signature Da |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| August 10, 2021 |
SEC File Number: 001-38942 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 10, 2021 |
EXHIBIT 10.33 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FRAMEWORK DRUG SUBSTANCE SUPPLY AGREEMENT This FRAMEWORK DRUG SUBSTANCE SUPPLY AGREEMENT (this ?Agreement?), dated as of the 29th day of July, 2021 (the ?Signature Date?), is being entered into by |
|
| August 9, 2021 | ||
| August 9, 2021 |
Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress ARCT-021, Arcturus? single shot STARR? mRNA COVID vaccine, to begin multinational placebo-controlled Phase 3 efficacy study funded and sponsored by a global entity ARCT-154, Arcturus? STARR? mRNA vaccine candidate targeting COVID variants of concern, elicits robust neutralizing antibody titers against all variants tested in primates, including the Delta variant ARCT-154 to begin staged Phase 3 study in Vietnam; potential for EUA in December Investor conference call at 4:30 p. |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| August 4, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| June 22, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| May 10, 2021 |
Quarterly Report - ARCT 10-Q 20210331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) (C |
|
| May 10, 2021 |
Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data ARCT-021 Phase 2 interim data showed favorable safety profile and greater than 90% seroconversion after a single dose; data supports advancement into Phase 3 In negotiations with multiple regulatory authorities regarding ARCT-021 Phase 3 study program Continued progress advancing mRNA therapeutic platform, including liver (ARCT-810) and lung (ARCT-032) targeted programs Investor conference call at 4:30 p. |
|
| May 10, 2021 | ||
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO.) Filed by the Registrant?? Filed by a Party other than the Registrant?? Check the appropriate box: ??Preliminary Proxy Statement ??Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ??Defini |
|
| April 26, 2021 |
EXHIBIT 10.1 Severance Policy for Executives This Severance Policy for Executives (this ?Policy?) of Arcturus Therapeutics Holdings Inc. (including its subsidiaries, the ?Company?) shall be effective as of May 1, 2021 and refers to any circumstance under which a covered Executive ceases to be part of the Company?s workforce. It is beneficial for all parties that the employment separation process i |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2021 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| March 1, 2021 |
Exhibit 10.29 Page - 1 SECOND AMENDMENT TO LEASE This SECOND Amendment to Lease (the ?Amendment?) is made this , 2020 (the ?Effective Date?), by and between ARE-SD Region No. 44, LLC, a Delaware limited liability company (?Landlord?), and ARCTURuS THERAPEUTICS, INC., a Delaware corporation (?Tenant?). RECITALS A.Landlord and Tenant are parties to a certain Lease Agreement dated as of October 4, 20 |
|
| March 1, 2021 |
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates ARCT-021 single-shot COVID-19 STARR™ mRNA vaccine to be advanced to Phase 3 clinical development – on track to initiate Phase 3 study in Q2 ARCT-021 single shot immunogenicity profile compares favorably with new data generated from recipients of a single dose of an approved conventiona |
|
| March 1, 2021 | ||
| March 1, 2021 |
Exhibit 4.1 Common Stock As of February 24, 2021, there were 26,205,562 shares of common stock outstanding. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. The holders of common stock are not entitled to cumulative voting rights with respect to the election of directors, and as a consequence, minority st |
|
| March 1, 2021 |
Exhibit 10.30 Page - 1 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (the "Amendment") is made this February 25, 2021 (the "Effective Date"), by and between ARE-SD REGION NO. 44, LLC, a Delaware limited liability company ("Landlord"), and ARCTURUS THERAPEUTICS, INC., a Delaware corporation ("Tenant"). RECITALS A.Landlord and Tenant are parties to a ce1tain Lease Agreement dated as of Octo |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| March 1, 2021 |
Annual Report - ARCT 10-K 20201231 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38942 ARCTURUS THERAP |
|
| February 22, 2021 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporatio |
|
| February 22, 2021 |
EXHIBIT 99.1 Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals SAN DIEGO-(BUSINESS WIRE)-Feb. 22, 2021- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within live |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Arcturus Therapeutics Holdings Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969T109 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 12, 2021 |
SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* Arcturus Therapeutics Holdings Inc (Name of Issuer) Common Stock (Title of Class of Securities) 03969T109 (CUSIP Number) December 31, 2020 (Date of Event Whic |
|
| February 12, 2021 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2021 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation |
|
| January 8, 2021 |
OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) ARCTURUS THERAPEUTICS HOLDINGS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03969T109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires |
|
| December 10, 2020 |
ARCT / Arcturus Therapeutics Ltd. / Ultragenyx Pharmaceutical Inc. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) ARCTURUS THERAPEUTICS HOLDINGS INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03969T109 (CUSIP Number) Karah Parschauer Executive Vice President, General Counsel Ultragenyx Pharmaceutical Inc. 60 Lev |
|
| December 8, 2020 |
CALCULATION OF REGISTRATION FEE Filed Pursuant to Rule 424(b)(5) Registration No. 333-251175 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be registered(1) Maximum Offering Price Per Share Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.001 par value 1,569,750 $110.00 $172,672,500.00 $18,838.57 (1)Assumes exercise in full of the underwriters’ option t |
|
| December 8, 2020 |
Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock SAN DIEGO, December 7, 2020 (GLOBE NEWSWIRE) - Arcturus Therapeutics Holdings Inc. |
|
| December 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2020 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation |
|
| December 8, 2020 |
1,365,000 Shares of Common Stock Arcturus Therapeutics Holdings Inc. UNDERWRITING AGREEMENT December 7, 2020 Piper Sandler & Co. Guggenheim Securities, LLC Wells Fargo Securities, LLC As Representatives of the several Underwriters named in Schedule I attached hereto c/o Piper Sandler & Co. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota 55402 c/o Guggenheim Securities, LLC 330 Madison Avenue N |
|
| December 8, 2020 | ||
| December 7, 2020 |
Exhibit 4.1 ARCTURUS THERAPEUTICS HOLDINGS INC. Issuer AND as Trustee INDENTURE Dated as of , 20 Debt Securities CROSS-REFERENCE TABLE(1) SECTION OF TRUST INDENTURE ACT OF 1939, AS AMENDED SECTION(S) OF INDENTURE 310(a) 7.9 310(b) 7.8 311(a) 7.13 311(b) 7.13 312(a) 5.1, 5.2(a) 312(b) 5.2(b) 312(c) 5.2(c) 313(a) 5.4 313(b) 5.4 313(c) 5.4 313(d) 5.4 314(a) 5.3, 14.12 314(c) 14.7(a) 314(e) 14.7(b) 31 |
|
| December 7, 2020 |
Fourth Amendment to Loan and Security Agreement, dated December 1, 2020 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Fourth Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of December 1, 2020, by and between WESTERN ALLIANCE BANK, an Arizona corporation (“Bank”), and ARCTURUS THERAPEUTICS, INC. |
|
| December 7, 2020 |
Subject to Completion, dated December 7, 2020 Filed Pursuant to Rule 424(b)(5) Registration No. 333-251175 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| December 7, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation |
|
| December 7, 2020 |
S-3ASR 1 e620120s3asr-at.htm As filed with the Securities and Exchange Commission on December 7, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpo |
|
| November 25, 2020 |
Certificate of Amendment, dated November 25, 2020 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| November 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2020 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporatio |
|
| November 13, 2020 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporatio |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation |
|
| November 9, 2020 |
Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data Investor conference call at 4:30 p. |
|
| November 9, 2020 |
CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| November 9, 2020 |
CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| October 15, 2020 |
Financial Statements and Exhibits, Other Events - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2020 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation |
|
| October 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.) Filed by the Registrant?? Filed by a Party other than the Registrant?? Check the appropriate box: ? ?Preliminary Proxy Statement ? ?Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ?Def |
|
| October 9, 2020 |
ARCT / Arcturus Therapeutics Ltd. / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| October 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| October 2, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2020 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporati |
|
| September 11, 2020 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| September 11, 2020 |
ARCT / Arcturus Therapeutics Ltd. / HealthCor Management, L.P. - SC 13G Passive Investment SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* Arcturus Therapeutics Holdings Inc (Name of Issuer) Common Stock (Title of Class of Securities) 03969T109 (CUSIP Number) September 1, 2020 (Date of Event Which |
|
| August 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2020 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| August 18, 2020 |
Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health SAN DIEGO, Aug. |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) |
|
| August 10, 2020 |
Quarterly Report - 10-Q 20200630 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. |
|
| August 10, 2020 |
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update COVID-19 STARR™ mRNA vaccine candidate, ARCT-021 (LUNAR-COV19) has initiated Phase 1/2 clinical study with Duke-NUS Medical School; Dosing anticipated imminently, initial data expected Q4 ARCT-810 (LUNAR-OTC), mRNA therapeutic candidate for ornithine transcarbamylase (OTC) deficiency, Phase 1 healthy volunteer study continues to advance, initial results expected Q4 Successfully raised approximately $280 million in gross proceeds through two public equity offerings in 2020 to advance promising clinical stage pipeline Investor Conference Call at 4:30 p. |
|
| August 5, 2020 |
As filed with the Securities and Exchange Commission on August 4, 2020 Registration No. |
|
| August 5, 2020 |
Amended and Restated 2019 Omnibus Equity Incentive Plan ARCTURUS THERAPEUTICS HOLDINGS INC. AMENDED & RESTATED 2019 OMNIBUS EQUITY INCENTIVE PLAN (Originally Effective June 10, 2019; Amended & Restated April 26, 2020) ARTICLE 1. EFFECTIVE DATE, OBJECTIVES AND DURATION 1.1 Effective Date of the Plan. The Board of Directors of ARCTURUS THERAPEUTICS HOLDINGS INC., a Delaware corporation (the “Company”), originally adopted the 2019 OMNIBUS EQUITY INCENTIVE |
|
| August 5, 2020 |
As filed with the Securities and Exchange Commission on August 4, 2020 Registration No. |
|
| August 5, 2020 |
2020 Employee Stock Purchase Plan ARCTURUS THERAPEUTICS HOLDINGS INC. 2020 EMPLOYEE STOCK PURCHASE PLAN TABLE OF CONTENTS Page Article 1. Purpose and Effective Date 2 1.1 Effective Date 2 1.2 Purpose. 2 Article 2. Definitions 2 2.1 “Account” 2 2.2 “Administrator” 2 2.3 “Accumulation Period” 2 2.4 “Base Earnings” 2 2.5 “Board” 2 2.6 “Code” 2 2.7 “Cut-Off Date” 3 2.8 “Effective Date” 3 2.9 “Eligible Employee” 3 2.10 “Employee” 3 2.1 |
|
| July 30, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-238139 PROSPECTUS SUPPLEMENT (To prospectus dated May 21, 2020) 3,264,151 Shares Common Stock We are offering an aggregate of 3,264,151 shares of our common stock pursuant to this prospectus supplement and accompanying prospectus. Our common stock is listed on the Nasdaq Global Market under the symbol “ARCT.” The last reported sale price of our |
|
| July 29, 2020 |
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) - Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today anno |
|
| July 29, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2020 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| July 29, 2020 |
EX-1.1 2 e619811ex1-1.htm 3,264,151 Shares of Common Stock Arcturus Therapeutics Holdings Inc. UNDERWRITING AGREEMENT July 28, 2020 Citigroup Global Markets Inc. Guggenheim Securities, LLC Barclays Capital Inc. As Representatives of the several Underwriters named in Schedule I attached hereto c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Guggenheim Securities, |
|
| July 28, 2020 |
Subject to Completion, dated July 28, 2020 Filed Pursuant to Rule 424(b)(5) Registration No. 333-238139 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| July 24, 2020 |
EXHIBIT 99.1 Israel secures rights to stockpile and reserve doses of LUNAR-COV19 for its citizens Israel is the second country to reserve supply of LUNAR-COV19 SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) - Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization |
|
| July 24, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2020 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| June 19, 2020 |
June 19, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 RE: Arcturus Therapeutics Holdings Inc. Registration Statement on Form S-3/A (File No. 333-235475) Filed May 22, 2020 Pursuant to Rules 460 and 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Arcturus Therapeutics Holdings Inc. |
|
| June 18, 2020 | ||
| June 18, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2020 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation) ( |
|
| June 9, 2020 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38942 32-0595345 (State or other jurisdiction of incorporation |
